MX2014012295A - Anticuerpos anti-ad amts-5, derivados y usos de los mismos. - Google Patents
Anticuerpos anti-ad amts-5, derivados y usos de los mismos.Info
- Publication number
- MX2014012295A MX2014012295A MX2014012295A MX2014012295A MX2014012295A MX 2014012295 A MX2014012295 A MX 2014012295A MX 2014012295 A MX2014012295 A MX 2014012295A MX 2014012295 A MX2014012295 A MX 2014012295A MX 2014012295 A MX2014012295 A MX 2014012295A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- amino acid
- acid sequence
- identity
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6416—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12164107.0A EP2650310B1 (en) | 2012-04-13 | 2012-04-13 | Anti-ADAMTS-5 antibody, derivatives and uses thereof |
| PCT/EP2013/057649 WO2013153189A1 (en) | 2012-04-13 | 2013-04-12 | Anti-adamts-5 antibody, derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014012295A true MX2014012295A (es) | 2014-11-10 |
Family
ID=48083198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014012295A MX2014012295A (es) | 2012-04-13 | 2013-04-12 | Anticuerpos anti-ad amts-5, derivados y usos de los mismos. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9631029B2 (enExample) |
| EP (2) | EP2650310B1 (enExample) |
| JP (1) | JP2015518476A (enExample) |
| KR (1) | KR20150003278A (enExample) |
| CN (1) | CN104245737B (enExample) |
| AR (1) | AR090668A1 (enExample) |
| AU (1) | AU2013246880B2 (enExample) |
| CA (1) | CA2869031A1 (enExample) |
| DK (1) | DK2650310T3 (enExample) |
| ES (1) | ES2588484T3 (enExample) |
| HK (1) | HK1202296A1 (enExample) |
| HU (1) | HUE031089T2 (enExample) |
| IN (1) | IN2014MN01868A (enExample) |
| MX (1) | MX2014012295A (enExample) |
| PL (1) | PL2650310T3 (enExample) |
| PT (1) | PT2650310T (enExample) |
| RU (1) | RU2014145536A (enExample) |
| TW (1) | TWI579302B (enExample) |
| WO (1) | WO2013153189A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3501B1 (ar) | 2014-12-22 | 2020-07-05 | Servier Lab | مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام) |
| US10053515B2 (en) | 2016-01-22 | 2018-08-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor XI antibodies |
| GB201610056D0 (en) | 2016-06-09 | 2016-07-27 | Galapagos Nv And Laboratoires Servier Les | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis |
| GB201610055D0 (en) | 2016-06-09 | 2016-07-27 | Galapagos Nv And Laboratoires Servier Les | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis |
| EA201892716A1 (ru) | 2016-06-14 | 2019-05-31 | Мерк Шарп И Доум Корп. | Антитела к фактору свертывания xi |
| US11261260B2 (en) | 2017-06-02 | 2022-03-01 | Merck Patent Gmbh | ADAMTS binding immunoglobulins |
| IT201800003818A1 (it) * | 2018-03-21 | 2019-09-21 | Fond Per Listituto Oncologico Di Ricerca Ior | Nuovi farmaci prosenescenza |
| FI129515B (en) | 2020-11-06 | 2022-03-31 | Salarusta Oy | FOR USE IN THE PREVENTION AND / OR TREATMENT OF A DISEASE OR CONDITION RELATED TO THE DEGRADATION AND / OR DISTURBANCE OF THE DEGREE OF MONTOOSASE AND / OR INTEGRITY |
| AU2021399788A1 (en) | 2020-12-15 | 2023-08-03 | Lakefront Biotherapeutics Nv | Solid forms of (5s)-cyclopropyl-5-[3-[(3s)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione |
| CN116256518B (zh) * | 2023-02-24 | 2025-07-04 | 北京爱德诺生物科技有限公司 | 一种肿瘤诊断标志物及其诊断试剂盒和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5484590A (en) * | 1993-09-09 | 1996-01-16 | La Jolla Cancer Research Foundation | Expression of the developmental I antigen by a cloned human cDNA encoding a member of a β-1,6-N-acetylglucosaminyltransferase gene family |
| WO2000053774A2 (en) | 1999-03-08 | 2000-09-14 | Neurocrine Biosciences, Inc. | Metalloproteinases and methods of use therefor |
| US6391610B1 (en) * | 1999-08-06 | 2002-05-21 | The Cleveland Clinic Foundation | Nucleic acids encoding zinc metalloproteases |
| BR0318625A (pt) * | 2003-12-04 | 2006-10-31 | Wyeth Corp | biaril sulfonamidas e métodos para usar as mesmas |
| SG177288A1 (en) | 2009-07-02 | 2012-02-28 | Glaxo Group Ltd | Polypeptides and method of treatment |
-
2012
- 2012-04-13 ES ES12164107.0T patent/ES2588484T3/es active Active
- 2012-04-13 DK DK12164107.0T patent/DK2650310T3/en active
- 2012-04-13 PT PT121641070T patent/PT2650310T/pt unknown
- 2012-04-13 HU HUE12164107A patent/HUE031089T2/en unknown
- 2012-04-13 PL PL12164107T patent/PL2650310T3/pl unknown
- 2012-04-13 EP EP12164107.0A patent/EP2650310B1/en not_active Not-in-force
-
2013
- 2013-04-09 TW TW102112480A patent/TWI579302B/zh not_active IP Right Cessation
- 2013-04-12 KR KR1020147031200A patent/KR20150003278A/ko not_active Ceased
- 2013-04-12 JP JP2015504963A patent/JP2015518476A/ja active Pending
- 2013-04-12 MX MX2014012295A patent/MX2014012295A/es unknown
- 2013-04-12 RU RU2014145536A patent/RU2014145536A/ru not_active Application Discontinuation
- 2013-04-12 AR ARP130101191A patent/AR090668A1/es unknown
- 2013-04-12 CN CN201380019819.6A patent/CN104245737B/zh not_active Expired - Fee Related
- 2013-04-12 HK HK15102792.9A patent/HK1202296A1/xx unknown
- 2013-04-12 IN IN1868MUN2014 patent/IN2014MN01868A/en unknown
- 2013-04-12 US US14/390,466 patent/US9631029B2/en not_active Expired - Fee Related
- 2013-04-12 EP EP13715240.1A patent/EP2836516B1/en not_active Not-in-force
- 2013-04-12 CA CA2869031A patent/CA2869031A1/en not_active Abandoned
- 2013-04-12 WO PCT/EP2013/057649 patent/WO2013153189A1/en not_active Ceased
- 2013-04-12 AU AU2013246880A patent/AU2013246880B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DK2650310T3 (en) | 2016-09-12 |
| WO2013153189A1 (en) | 2013-10-17 |
| EP2650310B1 (en) | 2016-06-08 |
| EP2650310A1 (en) | 2013-10-16 |
| US20150056210A1 (en) | 2015-02-26 |
| RU2014145536A (ru) | 2016-06-10 |
| US9631029B2 (en) | 2017-04-25 |
| AU2013246880B2 (en) | 2016-04-21 |
| CA2869031A1 (en) | 2013-10-17 |
| CN104245737A (zh) | 2014-12-24 |
| HK1202296A1 (en) | 2015-09-25 |
| JP2015518476A (ja) | 2015-07-02 |
| TW201402606A (zh) | 2014-01-16 |
| EP2836516B1 (en) | 2017-07-26 |
| PT2650310T (pt) | 2016-09-01 |
| CN104245737B (zh) | 2017-04-05 |
| TWI579302B (zh) | 2017-04-21 |
| HUE031089T2 (en) | 2017-06-28 |
| PL2650310T3 (pl) | 2017-01-31 |
| IN2014MN01868A (enExample) | 2015-07-03 |
| AU2013246880A1 (en) | 2014-10-16 |
| EP2836516A1 (en) | 2015-02-18 |
| AR090668A1 (es) | 2014-11-26 |
| KR20150003278A (ko) | 2015-01-08 |
| ES2588484T3 (es) | 2016-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2836516B1 (en) | Anti-adamts-5 antibody, derivatives and uses thereof | |
| AU2012253434B2 (en) | Methods of treating or preventing cholesterol related disorders | |
| US20080177045A1 (en) | Monoclonal antibodies against ANGPTL3 | |
| KR20170082631A (ko) | 뇌졸중의 치료 또는 예방 방법 | |
| AU2020256388A1 (en) | Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders | |
| EP2615114A2 (en) | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) | |
| NZ618300B2 (en) | Methods of treating or preventing cholesterol related disorders | |
| HK1195504B (en) | Methods of treating or preventing cholesterol related disorders | |
| NZ734570B2 (en) | Methods of treating or preventing cholesterol related disorders |